Remarkable response to pembrolizumab with platinum‐doublet in PD‐L1‐low pulmonary sarcomatoid carcinoma: A case report
Sign Up to like & getrecommendations! Published in 2021 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.13890
Abstract: Pulmonary sarcomatoid carcinoma (SC) is an aggressive subtype of lung cancer that exhibits resistance to cytotoxic chemotherapy. Although programmed cell death 1 (PD‐1) inhibitors have been reported to show antitumor effects in patients with high… read more here.
Keywords: response; response pembrolizumab; pulmonary sarcomatoid; remarkable response ... See more keywords